Skip to Content

Dojolvi Approval History

FDA Approved: Yes (First approved June 30, 2020)
Brand name: Dojolvi
Generic name: triheptanoin
Dosage form: Oral Liquid
Company: Ultragenyx Pharmaceutical Inc.
Treatment for: Long-Chain Fatty Acid Oxidation Disorders

Dojolvi (triheptanoin) is a medium-chain triglyceride indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

Development History and FDA Approval Process for Dojolvi

DateArticle
Jun 30, 2020Approval FDA Approves Dojolvi (triheptanoin) for the Treatment of Long-Chain Fatty Acid Oxidation Disorders
Oct 14, 2019Ultragenyx Announces FDA Accepts New Drug Application for UX007 (triheptanoin) for Treatment of Long-chain Fatty Acid Oxidation Disorders
Aug  1, 2019Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders
Nov 14, 2018Ultragenyx Announces Intent to Submit New Drug Application to U.S. FDA for UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Mid-2019
Apr 23, 2015Ultragenyx Granted Additional Orphan Drug Designations for Triheptanoin
Dec 17, 2013Ultragenyx Investigational New Drug Application for Triheptanoin for the Treatment of Glucose Transporter Type-1 Deficiency Syndrome is in Effect

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.